Masitinib Shows Survival Benefits For GIST

Masitinib shows a promising benefit–risk ratio in the treatment of advanced gastrointestinal stromal tumour...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.